tiprankstipranks
Advertisement
Advertisement

EKF Diagnostics Tightens Capital Structure With Treasury Share Buyback

Story Highlights
  • EKF Diagnostics repurchased 280,000 shares into treasury, trimming free-float voting stock.
  • Part of the buyback came from Harwood-managed funds to keep director Mills’ stake below 30%.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
EKF Diagnostics Tightens Capital Structure With Treasury Share Buyback

Claim 30% Off TipRanks

EKF Diagnostics Holdings ( (GB:EKF) ) has shared an update.

EKF Diagnostics Holdings has repurchased 280,000 of its ordinary shares at a weighted average price of 26.175 pence, with the shares to be held in treasury, reducing the number of shares in issue carrying voting rights to 432,300,112. As part of the buyback, EKF acquired 80,000 shares from funds managed by Harwood to maintain Non-Executive Director Christopher Mills’ aggregate indirect beneficial interest at around 127.5 million shares and ensure his holding does not exceed 30% of the company’s voting rights, a move that fine-tunes EKF’s capital structure and preserves its shareholder governance balance.

The most recent analyst rating on (GB:EKF) stock is a Hold with a £29.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.

Spark’s Take on GB:EKF Stock

According to Spark, TipRanks’ AI Analyst, GB:EKF is a Neutral.

EKF Diagnostics Holdings receives a score of 67, driven by strong financial performance and a positive earnings call. The company’s robust balance sheet and improved profitability are significant strengths. However, technical indicators suggest potential bearish momentum, and the valuation is moderate. The positive outlook from the earnings call, including strategic growth plans and a share buyback program, enhances the overall score.

To see Spark’s full report on GB:EKF stock, click here.

More about EKF Diagnostics Holdings

EKF Diagnostics Holdings plc is an AIM-listed global diagnostics business specialising in point-of-care analysers in hematology and diabetes, as well as life sciences services that provide specialist manufacture of enzymes and custom products for diagnostic, food and industrial applications. Headquartered in Penarth near Cardiff, the company operates five manufacturing sites across the US and Germany and sells into more than 120 countries worldwide.

Average Trading Volume: 352,408

Technical Sentiment Signal: Hold

Current Market Cap: £117.7M

Find detailed analytics on EKF stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1